How equitable are GP practice prescribing rates for statins?: An ecological study in four primary care trusts in north west England

International Journal for Equity in Health

Volumn 6, Issue , 2007, Pages

  Ward, Paul R ^a   Noyce, Peter R ^b   St Leger, Antony S ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ETHNICITY; FEMALE; GENERAL PRACTICE; HEALTH CARE; HEALTH CARE NEED; HUMAN; MALE; MULTIPLE REGRESSION; PRESCRIPTION; PRIMARY MEDICAL CARE; STATISTICAL ANALYSIS; THEORETICAL MODEL; UNITED KINGDOM;

EID: 34047209121     PISSN: None     EISSN: 14759276     Source Type: Journal    
DOI: 10.1186/1475-9276-6-2     Document Type: Article

References (62)

1. Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of healthcare need. PR Ward PR Noyce AS St Leger, International Journal for Equity in Health 2005 4 15701165
2. Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England. PR Ward PR Noyce AS St Leger, Therapeutics and Clinical Risk Management 2005 1 61 68 10.2147/tcrm.1.1.61.53599
3. Multivariate regression analysis of associations between general practitioner prescribing rates for coronary heart disease drugs and healthcare needs indicators. PR Ward PR Noyce AS St Leger, J Epidemiol Community Health 2005 59 86 87 15598733
4. Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. PR Ward PR Noyce AS St Leger, J Epidemiol Community Health 2004 58 89 96 10.1136/jech.58.2.89 14729882
5. Developing prevalence-based prescribing units for analysing variations in general practitioner prescribing: a case study using statins. PR Ward PR Noyce AS St Leger, J Clin Pharm Ther 2003 28 23 29 10.1046/j.1365-2710.2003.00451.x 12605615
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. J Shepherd S Cobbe I Ford CG Isles AR Lorimer PW MacFarlane JH McKillop CJ Packard, N Engl J Med 1995 333 1301 1307 10.1056/NEJM199511163332001 7566020
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JR Downs M Clearfield S Weis E Whitney DR Shapiro PA Beere A Langendorfer EA Stein W Kruyer AM Gotto Jr., JAMA 1998 279 1615 1622 10.1001/jama.279.20.1615 9613910
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). SSSS Group, Lancet 1994 344 1383 1389 7968073
9. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. FM Sacks MA Pfeffer LA Moye JL Rouleau JD Rutherford TG Cole L Brown JW Warnica JM Arnold CC Wun BR Davis E Braunwald, N Engl J Med 1996 335 1001 1009 10.1056/NEJM199610033351401 8801446
10. The use of statins: a case of misleading priorities? [Editorial.]. N Freemantle R Barbour R Johnson M Marchment A Kennedy, BMJ 1997 315 826 828 9353492
11. The primary prevention of coronary heart disease with statins: practice headache or public health? PH Evans, Br J Gen Pract 2000 50 695 697 11050782
12. Prescription of statins: cost implications of evidence-based treatment applied to a health authority population. N Bradshaw R Walker, J Clin Pharm Therapeutics 1997 22 379 389 10.1046/j.1365-2710.1997.00118.x
13. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. C Baxter R Jones L Corr, BMJ 1998 317 1134 1135 9784452
14. Statin prescribing in Nottingham general practices: a cross-sectional study. C Packham J Robinson J Morris C Richards P Marks D Gray, J Public Health Med 1999 21 60 64 10.1093/pubmed/21.1.60 10321861
15. Use of statins in general practices, 1996-8: cross sectional study. C Packham J Pearson J Robinson D Gray, BMJ 2000 320 1583 1584 10845969 10.1136/bmj.320.7249.1583
16. Age, sex and practice variations in the use of statins in general practice in England and Wales. A Majeed K Moser R Maxwell, J Public Health Med 2000 22 275 279 10.1093/pubmed/22.3.275 11077897
17. Lipid lowering drug use in older British men with established coronary heart disease: evidence of underuse. PH Whincup O Papacosta M Walker L Lennon A Thomson, Heart 2001 85 5 10.1136/heart.85.1.5 11119447
18. How should health policy be modified by the evidence of medical practice variations? K McPherson, Controversies in Health Care Policies. London, BMJ Publishing Group, Marinker M, 1994 55 74
19. Geographies of need and the new NHS: methodological issues in the definition and measurement of the health needs of local populations. A Gibson S Asthana P Brigham G Moon J Dicker, Health & Place 2002 8 47 60 10.1016/S1353-8292(01)00035-1 11852263
20. Explaining variation in statin prescribing: a practice based analysis. N Bradshaw DL Fone R Walker, Pharm J 1999 263 R19
21. J Le Grand, The Strategy of Equality. London, Allan & Unwin 1982
22. Equity of access to health care services: theory and evidence from the UK. M Goddard P Smith, Soc Sci Med 2001 53 1149 1162 10.1016/S0277-9536(00) 00415-9 11556606
23. The concepts and principles of equity and health. M Whitehead, Int J Health Services 1992 22 429 445
24. Equity in health. A Williams R Cookson, Handbook of Health Economics Amsterdam, Elsevier, Culyer AJ and Newhouse J, 2000
25. A taxonomy of social need. J Bradshaw, Problems and Progress in Medical Care Oxford, Nuffield Provincial Hospital Trust, McLachlan G, 1972
26. The conceptualisation and measurement of need. J Bradshaw, Researching the people's health London, Routledge, Popay J and Williams G, 1994 45 57
27. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. M Pignone C Phillips C Mulrow, BMJ 2000 321 983 986 11039962 10.1136/bmj.321.7267.983
28. Cholesterol and coronary heart disease: screening and treatment. S Ebrahim G Davey-Smith C McCabe N Payne M Pickin T Sheldon F Lampe F Sampson S Ward G Wannamthee, Quality in Health Care 1998 7 232 239 10339027
29. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. RP Byington W Jukema JT Salonen B Pitt AV Bruschke H Hoen CD Furberg J Mancini, Circulation 1995 92 2419 2425 7586340
30. Patients with acute coronary syndrome should start a statin while still in hospital. CG Isles, Heart 2002 88 5 6 10.1136/heart.88.1.5 12067927
31. Statins being prescribed for those "least in need". B Christie, BMJ 1999 318 827 10092243
32. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? FDA Reid DG Cook PH Whincup, Heart 2002 88 15 19 10.1136/heart.88.1.15 12067933
33. Liefstyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. EUROASPIRE II Group., Eur Heart J 2001 22 554 572 10.1053/euhj.2001.2610 11259143
34. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Groups, Lancet 2001 357 995 1001 10.1016/S0140-6736(00)04235-5 11293642
35. Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. PG Steg B Iung LJ Feldman D Cokkinos J Deckers KAA Fox U Keil AP Maggioni, Heart 2002 88 20 24 10.1136/heart.88.1.20 12067934
36. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. N Danchin O Grenier J Ferrieres C Cantet JP Cambou, Heart 2002 88 159 162 10.1136/heart.88.2.159 12117845
37. Undertreatment of hyperlipidaemia in the secondary prevention of coronary artery disease. SR Majumdar JH Gurwitz SB Soumerai, J Gen Intern Med 1999 14 711 717 10632815 10.1046/j.1525-1497.1999.02229.x
38. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. PH Whincup JR Emberson L Lennon M Walker O Papacosta A Thomson, Heart 2002 88 25 29 10.1136/heart.88.1.25 12067936
39. Geographic, demographic, and socioeconomic variations in the investigation and management of coronary heart disease in Scotland. MC MacLeod AR Finlayson JP Pell IN Findlay, Heart 1999 81 252 256 10026347
40. Variations in use of tertiary cardiac services in part of North-West England. A Gatrell G Lancaster A Chapple S Horsley M Smith, Health & Place 2002 8 147 153 10.1016/S1353-8292(01)00044-2 12135638
41. Gender differences in accessing cardiac surgery across England: a cross-sectional analysis of the health survey for England. W Dong Y Ben-Shlomo H Colhoun N Chaturvedi, Soc Sci Med 1998 47 1773 1780 10.1016/S0277-9536(98) 00242-1 9877347
42. Age and sex differences in the management of ischaemic heart disease. FA Majeed D Cook, Public Health 1996 110 7 12 10.1016/S0033-3506(96)80027-8 8685314
43. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. J Hippisley-Cox M Pringle N Crown A Meal A Wynn, BMJ 2001 322 832 11290638 10.1136/bmj.322.7290.832
44. Prescribing patterns in high-need Health Authority populations: how does an ethnically mixed composition affect volume and cost? M Hann J Cantrill D Baker P Gill, J Clin Pharm Therapeutics 2004 29 537 546 10.1111/j.1365-2710. 2004.00604.x
45. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. P Primatesta NR Poulter, BMJ 2000 321 1322 1325 11090516 10.1136/bmj.321.7272.1322
46. Prescribing of lipid lowering drugs to South Asian patients: ecological study. MG Patel DJ Wright PS Gill D Jerwood J Silcock H Chrystyn, BMJ 2002 325 25 26 12098726 10.1136/bmj.325.7354.25
47. Prescribing information systems; making sense of primary care data. SR Chapman, J Clin Pharm Therapeutics 2001 26 235 239 10.1046/j.1365-2710.2001. 00352.x
48. What can PACT tell us about prescribing in general practice? A Majeed N Evans P Head, BMJ 1997 315 1515 1519 9420496
49. Key Statistics from General Practice. Office of National Statistics, London, ONS 1998
50. Average daily quantities: a tool for measuring prescribing volume in England. T Walley DJ Roberts, Pharmacoepidemiol Drug Safety 2000 9 55 58 10.1002/(SICI)1099-1557(200001/02)9:1<55::AID-PDS467>3.0.CO;2-H
51. Prescribing Support Unit., Defined Daily Doses, Prescribed Daily Doses and Average Daily Quantities Leeds, Prescribing Support Unit 1997
52. Prescribing Support Unit., Average Daily Quantities and STAR(97)-PUs Leeds, PSU 2000
53. Low income scheme index: a new deprivation scale based on prescribing in general practice. DC Lloyd CM Harris DW Clucas, BMJ 1995 310 165 169 7833758
54. Using data from the 1991 census. FA Majeed DG Cook J Poloniecki D Martin, BMJ 1995 310 1511 1514 7787601
55. Evaluation of methods for calculating census health indicators for GP practices. RM Haynes AA Lovett SH Gale JS Brainard G Bentham, Public Health 1995 109 369 374 10.1016/S0033-3506(95)80009-3 7480602
56. Analysis from Inner London of deprivation payments based on enumeration districts rather than wards. T Crayford J Shanks M Bajekal S Langford, BMJ 1995 311 787 788 7580442
57. S Kerrison A Macfarlane, Official Health Statistics. An Unofficial Guide. London, Arnold 2000
58. Equity of health care: a ward-based analysis of primary care prescribing. N Bradshaw DL Fone R Walker, Pharm J 1998 261 R11
59. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. GC Fonarow WJ French LS Parsons H Sun JA Malmgren, Circulation 2001 103 38 44 11136683
60. Derivation of a needs based capitation formula for allocating prescribing budgets to health authorities and primary care groups in England: regression analysis. N Rice P Dixon DC Lloyd D Roberts, BMJ 2000 320 284 288 10650026 10.1136/bmj.320.7230.284
61. Department of Health., National Service Frameworks for Coronary Heart Disease London, Stationary Office 2000
62. Key Statistics from General Practice. Table 5C3: Persons prescribed drugs in selected BNF categories per 1000 patients by age, sex and calendar year - 1994-1998. Office for National Statistics., London, ONS 1998